|
Market Closed -
Nasdaq
00:00:00 29/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 10.62 USD | +3.51% |
|
+0.95% | +72.68% |
| 10-13 | ImmuCell Q3 Preliminary Sales Rise | MT |
| 10-13 | Immucell Corporation Reports Preliminary Unaudited Sales Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
Business description: ImmuCell Corporation

Number of employees: 73
Sales by Activity: ImmuCell Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Scours | - | 18.41M | 17.29M | 26.31M | 27.45M |
Mastitis | - | 155K | 178K | 179K | 196K |
Biotechnology | 19.24M | - | - | - | - |
Other | - | 1.46K | - | - | - |
Geographical breakdown of sales: ImmuCell Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 16.62M | 17.02M | 15.95M | 22.89M | 24.39M |
Other | 2.62M | 1.55M | 1.52M | 3.6M | 3.25M |
Executive Committee: ImmuCell Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 01/11/2025 | |
Timothy Fiori
DFI | Director of Finance/CFO | 47 | 07/04/2025 |
| Comptroller/Controller/Auditor | - | - |
Composition of the Board of Directors: ImmuCell Corporation
| Director | Title | Age | Since |
|---|---|---|---|
David Tomsche
CHM | Chairman | 69 | 01/12/2013 |
Paul Wainman
BRD | Director/Board Member | 61 | 31/03/2014 |
Gloria Basse
BRD | Director/Board Member | 66 | 10/06/2020 |
| Director/Board Member | 54 | 01/11/2025 | |
Kathy Turner
BRD | Director/Board Member | 62 | 01/04/2026 |
| Director/Board Member | 64 | 15/04/2026 | |
Anthony DiMarco
BRD | Director/Board Member | 63 | 15/04/2026 |
Company details: ImmuCell Corporation

Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.51% | +0.95% | +72.40% | +123.11% | 96.45M | ||
| +0.50% | +1.38% | +57.09% | +129.96% | 1,148B | ||
| +0.86% | +5.14% | +45.00% | +86.15% | 652B | ||
| -0.14% | +0.42% | +25.69% | +105.85% | 505B | ||
| +0.49% | +2.14% | +53.80% | +65.98% | 384B | ||
| -0.63% | -5.97% | +61.93% | +37.06% | 348B | ||
| +1.98% | +2.23% | +33.77% | +55.69% | 294B | ||
| +0.99% | -0.60% | +2.72% | +26.27% | 264B | ||
| +0.87% | +3.08% | +54.69% | +72.74% | 244B | ||
| +0.08% | +3.67% | +35.05% | +107.78% | 197B | ||
| Average | +0.86% | +1.34% | +44.21% | +81.06% | 403.73B | |
| Weighted average by Cap. | +0.53% | +1.50% | +44.84% | +89.05% |
- Stock Market
- Stocks
- ICCC Stock
- Company ImmuCell Corporation
Select your edition
All financial news and data tailored to specific country editions

















